On February 10, 2026 Fina Biotech reported that the European Patent Office (EPO) has granted patent number EP2951315 to protect a ´NON-INVASIVE DIAGNOSTIC METHOD FOR DIAGNOSING BLADDER CANCER´ (NICHTINVASIVES DIAGNOSEVERFAHREN ZUR DIAGNOSE VON BLASENKREBS-
PROCÉDÉ DE DIAGNOSTIC NON INVASIF POUR DIAGNOSTIQUER LE CANCER DE LA VESSIE). The patent has been validated in Germany, France and UK and will be in force until January 31st, 2034.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The object of this patent relates to a non-invasive bladder cancer diagnosis method based on the detection and quantification in spontaneous urine of the gene expression of certain genes and/or combinations thereof acting as genetic markers of said disease. Likewise, the use of said genes as bladder cancer diagnosis genetic markers is an object of the present invention, developed by Fina Biotech in collaboration Dr. Antonio Alcaraz and his team at the Hospital Clinic de Barcelona (Spain). Another object of the patent also relates to a bladder cancer diagnosis kit based on the use of several combinations of said genes that have proven to be useful to non-invasively diagnose bladder cancer.

This new patent strengthens the intellectual property portfolio of Fina Biotech and confirms the company strategic commitment in developing non-invasive diagnostic tools useful for patients, doctors and healthcare providers.

(Press release, Fina Biotech, FEB 10, 2026, View Source [SID1234662711])